Federica Vecchio1, Gloria Messina2, Anna Giovenzana1, Alessandra Petrelli3. 1. San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. 2. Vita-Salute San Raffaele University, Milan, Italy. 3. San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. petrelli.alessandra@hsr.it.
Abstract
PURPOSE OF REVIEW: Type 1 diabetes (T1D) is one of the most frequent chronic autoimmune diseases in humans, characterized by the lack of insulin production resulting in high blood glucose levels and lifelong requirement of exogenous insulin administration for survival. It is now recognized that the autoimmune process begins years before the clinical onset, in a stage called pre-symptomatic T1D, in which the presence of β-cell-specific autoantibodies is detectable. Our aim is to review evidence for T1D as a "whole-pancreas disease," featured by both endocrine and exocrine pancreas alterations already at early disease stages. RECENT FINDINGS: In this review, we discuss a series of recent observations indicating that in genetically predisposed individuals, structural and functional abnormalities as well as immune cell infiltration of the exocrine pancreas are already present in the pre-symptomatic stages of the disease. Despite T1D being considered a β-cell-specific disease, numerous reports point to the presence of exocrine pancreas subclinical abnormalities occurring during disease development. These observations challenge the long-standing idea that T1D exocrine damage exists as a mere consequence of disease progression and provide further explanation of mechanisms underlying T1D pathogenesis.
PURPOSE OF REVIEW: Type 1 diabetes (T1D) is one of the most frequent chronic autoimmune diseases in humans, characterized by the lack of insulin production resulting in high blood glucose levels and lifelong requirement of exogenous insulin administration for survival. It is now recognized that the autoimmune process begins years before the clinical onset, in a stage called pre-symptomatic T1D, in which the presence of β-cell-specific autoantibodies is detectable. Our aim is to review evidence for T1D as a "whole-pancreas disease," featured by both endocrine and exocrine pancreas alterations already at early disease stages. RECENT FINDINGS: In this review, we discuss a series of recent observations indicating that in genetically predisposed individuals, structural and functional abnormalities as well as immune cell infiltration of the exocrine pancreas are already present in the pre-symptomatic stages of the disease. Despite T1D being considered a β-cell-specific disease, numerous reports point to the presence of exocrine pancreas subclinical abnormalities occurring during disease development. These observations challenge the long-standing idea that T1D exocrine damage exists as a mere consequence of disease progression and provide further explanation of mechanisms underlying T1D pathogenesis.
Authors: Jason L Gaglia; Alexander R Guimaraes; Mukesh Harisinghani; Stuart E Turvey; Richard Jackson; Christophe Benoist; Diane Mathis; Ralph Weissleder Journal: J Clin Invest Date: 2010-12-01 Impact factor: 14.808
Authors: Alexander M de Bruin; Sten F Libregts; Marijke Valkhof; Louis Boon; Ivo P Touw; Martijn A Nolte Journal: Blood Date: 2011-11-23 Impact factor: 22.113
Authors: Philip D Hardt; Annette Hauenschild; Jens Nalop; Axel M Marzeion; Clemens Jaeger; Joachim Teichmann; Reinhard G Bretzel; Manfred Hollenhorst; Hans U Kloer Journal: Pancreatology Date: 2003-09-24 Impact factor: 3.996
Authors: Moritz Leppkes; Christian Maueröder; Sebastian Hirth; Stefanie Nowecki; Claudia Günther; Ulrike Billmeier; Susanne Paulus; Mona Biermann; Luis E Munoz; Markus Hoffmann; Dane Wildner; Andrew L Croxford; Ari Waisman; Kerri Mowen; Dieter E Jenne; Veit Krenn; Julia Mayerle; Markus M Lerch; Georg Schett; Stefan Wirtz; Markus F Neurath; Martin Herrmann; Christoph Becker Journal: Nat Commun Date: 2016-03-11 Impact factor: 14.919
Authors: John Virostko; Jon Williams; Melissa Hilmes; Chris Bowman; Jordan J Wright; Liping Du; Hakmook Kang; William E Russell; Alvin C Powers; Daniel J Moore Journal: Diabetes Care Date: 2018-12-14 Impact factor: 19.112
Authors: Jeffrey C Barrett; David G Clayton; Patrick Concannon; Beena Akolkar; Jason D Cooper; Henry A Erlich; Cécile Julier; Grant Morahan; Jørn Nerup; Concepcion Nierras; Vincent Plagnol; Flemming Pociot; Helen Schuilenburg; Deborah J Smyth; Helen Stevens; John A Todd; Neil M Walker; Stephen S Rich Journal: Nat Genet Date: 2009-05-10 Impact factor: 38.330
Authors: Pascal de Boer; Nicole M Pirozzi; Anouk H G Wolters; Jeroen Kuipers; Irina Kusmartseva; Mark A Atkinson; Martha Campbell-Thompson; Ben N G Giepmans Journal: Nat Commun Date: 2020-05-18 Impact factor: 14.919
Authors: Timothy P Foster; Brittany Bruggeman; Martha Campbell-Thompson; Mark A Atkinson; Michael J Haller; Desmond A Schatz Journal: Endocr Pract Date: 2020-12 Impact factor: 3.443
Authors: Silvia Garavelli; Sara Bruzzaniti; Elena Tagliabue; Francesco Prattichizzo; Dario Di Silvestre; Francesco Perna; Lucia La Sala; Antonio Ceriello; Enza Mozzillo; Valentina Fattorusso; Pierluigi Mauri; Annibale A Puca; Adriana Franzese; Giuseppe Matarese; Mario Galgani; Paola de Candia Journal: Int J Mol Sci Date: 2020-01-11 Impact factor: 5.923